Русский
Treatment Of Operable And Relatively Operable Forms Of Breast Cancer
V.F. Semiglazov, G.A. Dashian, V.V. Semiglazov, R.V. Dovskih, R.M. Paltuev
Treatment of operable and relatively operable forms of breast cancer
It is expected that the control of early breast cancer (BC) further improve due to more effective and less toxic hormonal and cytotoxic drugs, new variants of targeted therapy, and individualization of therapeutic strategies for adjuvant systemic therapy. The problem of individual adjuvant treatment selection for each patient in routine clinical practice is discussed. Over the past decade, both taxanes and anthracyclines firmly establish itself as a leaders in the treatment of disseminated as well as early breast cancer. The results of evaluation of docetaxel (Taxotere) administration as a component of adjuvant and neoadjuvant chemotherapy of breast cancer are presented. Significant success is the development and implementation in the clinic practice trastuzumab (Herceptin), which is the antibody to the HER2 receptor. Targeted therapy with trastuzumab in addition to neoadjuvant chemotherapy significantly and reliably improves the response to treatment, leads to increase of survival rates of patients with HER2-positive localized or inflammatory breast cancer.
It is expected that the control of early breast cancer (BC) further improve due to more effective and less toxic hormonal and cytotoxic drugs, new variants of targeted therapy, and individualization of therapeutic strategies for adjuvant systemic therapy. The problem of individual adjuvant treatment selection for each patient in routine clinical practice is discussed. Over the past decade, both taxanes and anthracyclines firmly establish itself as a leaders in the treatment of disseminated as well as early breast cancer. The results of evaluation of docetaxel (Taxotere) administration as a component of adjuvant and neoadjuvant chemotherapy of breast cancer are presented. Significant success is the development and implementation in the clinic practice trastuzumab (Herceptin), which is the antibody to the HER2 receptor. Targeted therapy with trastuzumab in addition to neoadjuvant chemotherapy significantly and reliably improves the response to treatment, leads to increase of survival rates of patients with HER2-positive localized or inflammatory breast cancer.
Similar Articles
